Dextromethorphan/quinidine (AVP-923) Efficacy and Safety for Treatment of Agitation in Persons with Alzheimer's Disease: Results from a Phase 2 Study (NCT01584440)

Jeffrey Cummings,Paul Shin,Pierre Tariot,Constantine G Lyketsos,Uyen Nguyen,Nadine Knowles,Elaine Peskind,Joao Siffert

doi:10.1016/j.jagp.2014.12.171

Dextromethorphan/quinidine (AVP-923) Efficacy and Safety for Treatment of Agitation in Persons with Alzheimer's Disease: Results from a Phase 2 Study (NCT01584440)

Jeffrey Cummings, Paul Shin + Show 6 more

https://doi.org/10.1016/j.jagp.2014.12.171

Copy DOI

Journal: The American Journal of Geriatric Psychiatry	Publication Date: Mar 1, 2015
Citations: 5

Affiliation: Lou Ruvo Brain Institute, Cleveland Clinic, Avanir Pharmaceuticals (United States), Johns Hopkins Medicine, Johns Hopkins University, VA Puget Sound Health Care System, University of Washington

#Uncompetitive NMDA Antagonist #Combination Of Dextromethorphan + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Neuropsychiatric symptoms such as aggression/agitation are common in some patients with AD, adversely impact patient and caregiver quality of life and increase risk for institutionalization. No FDA-approved treatments exist for agitation in AD. AVP-923, a combination of dextromethorphan and low-dose quinidine (DM/Q), is being investigated for AD-related agitation. The CNS active component, dextromethorphan, is an uncompetitive NMDA antagonist, sigma-1 agonist, and serotonin/norepinephrine reuptake inhibitor.

Full Text